RSV Vaccine Market To Reach USD 2.2 Billion By 2032 | DataHorizzon Research
April 18, 2024 06:10 ET
|
DataHorizzon Research
Fort Collins, Colorado, April 18, 2024 (GLOBE NEWSWIRE) -- Growing prevalence of RSV in the population drives the need for RSV vaccines. RSV, a prevalent respiratory virus, often leads to severe...
Beslutninger på den ordinære generalforsamling 2024 i Bavarian Nordic A/S
April 16, 2024 12:20 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 16. april 2024 – Bavarian Nordic A/S (OMX: BAVA) har i dag afholdt ordinær generalforsamling med følgende resultater: Årsrapporten for 2023 blev godkendt. Bestyrelsens...
Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S
April 16, 2024 12:20 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, April 16, 2024 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2023 was adopted. The Board of Directors’...
Notice convening the Annual General Meeting in BioPorto A/S
April 04, 2024 05:07 ET
|
BioPorto A/S
April 4, 2024Announcement no. 6 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or...
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
April 02, 2024 02:00 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant...
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
April 02, 2024 02:00 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant...
Bavarian Nordic A/S - Indkaldelse til ordinær generalforsamling
March 21, 2024 07:00 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 21. marts 2024 – I overensstemmelse med vedtægternes §§ 10-14 indkaldes herved til ordinær generalforsamling i Bavarian Nordic A/S: Tirsdag den 16. april 2024 kl. 16.00 hos...
Bavarian Nordic A/S – Notice Convening Annual General Meeting
March 21, 2024 07:00 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, March 21, 2024 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on...
Bavarian Nordics mpox- og koppevaccine opnår godkendelse i Schweiz
March 13, 2024 08:29 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 13. marts 2024 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at lægemiddelmyndighederne i Schweiz, Swissmedic, har godkendt JYNNEOS® (MVA-BN) til aktiv immunisering mod sygdom...
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland
March 13, 2024 08:29 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, March 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved JYNNEOS® (MVA-BN) for active immunization...